Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta

Area of Science:

• Immunology
• Molecular Biology
• Cell Biology

Background:

• Protein kinase C (PKC) family members regulate immune cell survival.
• Ingenol 3-angelate (PEP005) induces apoptosis in acute myeloid leukemia (AML) cells via PKCdelta activation.
• PKC isoforms play critical roles in cellular fate decisions.

Purpose of the Study:

• To investigate the differential effects of PEP005 on T cells versus myeloid leukemia cells.
• To elucidate the specific PKC isoform and downstream pathways mediating PEP005's effects in T cells.
• To determine the role of PKC expression in dictating cellular responses to PEP005.

Main Methods:

• Treatment of human T cells and acute myeloid leukemia cell lines with PEP005.
• Analysis of PKC isoform activation and expression.
• Assessment of apoptosis rates and expression of anti-apoptotic proteins (Mcl-1, Bcl-x(L)).
• Use of dominant-negative PKC and ectopic expression of PKC for mechanistic studies.

Main Results:

• PEP005 activates PKC and promotes survival in resting and activated human T cells.
• This antiapoptotic effect in T cells is mediated by PKC activation, NFkappaB signaling, and increased Mcl-1 and Bcl-x(L) expression.
• PKC is expressed in T cells but absent in myeloid cells, explaining the differential response.
• Ectopic expression of PKC in AML cells reversed the pro-apoptotic effect of PEP005.

Conclusions:

• PEP005 acts as a survival factor for T cells by activating PKC and downstream anti-apoptotic pathways.
• The expression of functional PKC is a key determinant of whether PKC activation by PEP005 results in cell survival or apoptosis.
• These findings highlight cell-type-specific responses to PKC modulation and have implications for therapeutic strategies.